Second-line treatment for warm autoimmune anemia
Treatments studied
Part of Blood & lymphatic clinical trials.
This Phase 3 study tests a second-line treatment for adults with warm autoimmune hemolytic anemia whose disease is not controlled with steroids, who cannot tolerate steroids, or who decline standard treatment. It aims to improve anemia and reduce ongoing red blood cell destruction caused by the immune system.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 19 or older and have warm autoimmune hemolytic anemia confirmed by blood tests plus a positive direct antiglobulin test
- Your anemia is not improving with steroid treatment, you cannot tolerate steroids, or you chose not to use standard treatment
- Have no known “secondary cause” of the anemia (no underlying condition that caused it)
- Have no history or signs of lymphoma or other lymph-type cancers
- You cannot be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine for people with autoimmune hemolytic anemia (AIHA) that has not improved with standard treatments. The goal is to see if the drug can help control the disease and improve red blood cell counts.
This study tests a new treatment using your own immune cells, modified to target and destroy the faulty cells causing your anemia. It aims to provide a lasting remission for people whose disease has not responded to standard treatments.
This study tests a new drug called enatumab that may help people with a type of autoimmune anemia where the body attacks its own red blood cells. If you have not responded to previous treatments or your condition has returned, this trial might offer a new option to improve your hemoglobin levels.
This trial tests whether adding sirolimus (a medication that calms the immune system) to standard steroid treatment is better than steroids alone for people newly diagnosed with mild autoimmune hemolytic anemia (AIHA). It may help control the disease with fewer side effects.
This trial tests a new type of cell therapy called Inaticabtagene Autoleucel (a personalized treatment made from your own immune cells) for people with autoimmune hemolytic anemia that has not improved after three or more prior treatments. The goal is to see if this therapy can stop the immune system from destroying red blood cells and help increase your hemoglobin levels.
This trial studies sirolimus in adults with “warm” autoimmune hemolytic anemia (or Evans syndrome) when steroids have not worked or the anemia has returned. It may help control the immune attack on red blood cells, but there are specific safety checks for liver health and infections.
Hear when a new Primary Autoimmune Hemolytic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.